Apalutamide confers significant survival benefit for nmCRPC
02 Nov 2020
bởiAudrey Abella
In the prespecified, event-driven final analysis of the phase III SPARTAN* trial, adding the androgen receptor inhibitor (ARi) apalutamide to androgen deprivation therapy (ADT) significantly improved overall survival (OS) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).